Comparative Pharmacology
Head-to-head clinical analysis: TRIVORA 21 versus TRIVORA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIVORA 21 versus TRIVORA 28.
TRIVORA-21 vs TRIVORA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin release, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and reducing endometrial receptivity to implantation.
Combination oral contraceptive; suppresses gonadotropin release (FSH, LH) via estrogen (ethinyl estradiol) and progestin (levonorgestrel), preventing ovulation; increases cervical mucus viscosity, inhibiting sperm penetration; alters endometrial receptivity.
One tablet orally once daily for 21 days, followed by 7 placebo days.
One tablet containing 0.05 mg levonorgestrel and 0.03 mg ethinyl estradiol (first 21 tablets) and 7 inert tablets, taken orally once daily for 28 days, with 21 active followed by 7 placebo days.
None Documented
None Documented
Ethinyl estradiol: terminal half-life 13-27 hours (mean 17 hours); levonorgestrel: terminal half-life 11-45 hours (mean 25 hours). Clinical context: steady-state achieved after 3-5 half-lives (~3-5 days for ethinyl estradiol, ~5-9 days for levonorgestrel).
Ethinyl estradiol: 13-27 hours (mean 17 hours); norgestimate: active metabolite norelgestromin ~28 hours; levonorgestrel: ~20 hours. Supports daily dosing.
Renal (60%), fecal (40%) as metabolites; glucose and sulfate conjugates of ethinyl estradiol and levonorgestrel are excreted in bile and undergo enterohepatic circulation.
Renal (primary): 70% as metabolites (glucuronide and sulfate conjugates); biliary/fecal: 30%.
Category C
Category C
Oral Contraceptive (Estrogen/Progestin Combination)
Oral Contraceptive (Estrogen/Progestin Combination)